Pile, Kevin (2005) Methotrexate. In: Antirheumatic Therapy: actions and outcomes. Progress in Inflammation Research . Birkhauser , Switzerland, pp. 175-197.
|PDF (Published version) - Repository staff only - Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader|
This publication does not have an abstract. The Introduction is displayed as the abstract.
Methotrexate (MTX) is a folate analogue originally developed in the 1940s as a highly selective inhibitor of dihydrofolate reductase (DHFR). Its use in the reduction of rheumatoid arthritis (RA) synovitis was first reported in a 1951 paper on six RA patients by Gubner and Ginsburg and explained as a cytotoxic effect on proliferating lymphocytes. Subsequently its efficacy in RA was proven in a series of papers in the mid 1980s and it is now the mainstay of RA therapy, both alone and in combination, as recommended in the guidelines of the American College of Rheumatology 2002 .
|Item Type:||Book Chapter (Research - B1)|
|Keywords:||anti-rheumatic medications; methotrexate; pharmacology; rheumatoid arthritis|
|FoR Codes:||11 MEDICAL AND HEALTH SCIENCES > 1199 Other Medical and Health Sciences > 119999 Medical and Health Sciences not elsewhere classified @ 60%|
11 MEDICAL AND HEALTH SCIENCES > 1101 Medical Biochemistry and Metabolomics > 110199 Medical Biochemistry and Metabolomics not elsewhere classified @ 10%
11 MEDICAL AND HEALTH SCIENCES > 1103 Clinical Sciences > 110322 Rheumatology and Arthritis @ 30%
|SEO Codes:||92 HEALTH > 9201 Clinical Health (Organs, Diseases and Abnormal Conditions) > 920116 Skeletal System and Disorders (incl. Arthritis) @ 100%|
|Deposited On:||27 Jan 2010 11:30|
|Last Modified:||12 Feb 2011 03:05|
Last 12 Months: 0
Repository Staff Only: item control page